

Claims

1. Use of a compound of formula I:

5  $\text{RC(O)-NH-(CH}_2\text{)}_n\text{-CH=CH}_2$

wherein R represents  $\text{C}_{1-20}$  alkyl,  $\text{C}_{2-20}$  alkenyl or  $\text{C}_{2-20}$  alkynyl; and  
n is an integer from 0 to 3,

in the manufacture of a medicament for use in pain relief.

10

2. A compound of formula I as defined in claim 1 for use in medicine.

3. A method of providing pain relief to a patient comprising  
administering to said patient an effective amount of a compound of  
15 formula I, as defined in claim 1.

4. Use according to claim 1 or method according to claim 3 wherein the  
medicament further comprises one or more analgesics or the patient  
is administered said further one or more analgesics.

20

5. The use, compound or method of any of the previous claims wherein,  
in the compound of formula I, R represents  $\text{C}_{10-20}$  alkyl,  $\text{C}_{10-20}$  alkenyl  
or  $\text{C}_{10-20}$  alkynyl.

- 25 6. The use, compound or method of any of claims 1 to 4 wherein, in the  
compound of formula I, R represents  $\text{C}_{10-20}$  *n*-alkyl,  $\text{C}_{10-20}$  mono-  
alkenyl or  $\text{C}_{10-20}$  mono-alkynyl.

7. The use, compound or method of any of claims 1 to 4 wherein, in the compound of formula I, R represents C<sub>10-20</sub> *n*-alkyl, C<sub>10-20</sub> mono-*n*-alkenyl or C<sub>10-20</sub> mono-*n*-alkynyl.
- 5 8. The use, compound or method of any of claims 1 to 4 wherein, in the compound of formula I, R represents C<sub>11-19</sub> *n*-alkyl, or C<sub>11-19</sub> mono-*n*-alkenyl.
9. The use, compound or method of any of claims 1 to 4 wherein, in the  
10 compound of formula I, R represents C<sub>11-18</sub> *n*-alkyl, or C<sub>11-18</sub> mono-*n*-alkenyl.
10. The use, compound or method of any of claims 1 to 4 wherein, in the  
15 compound of formula I, the alkenyl or alkynyl groups have no more than 3 C-C double or triple bonds, respectively.
11. The use, compound or method of any of claims 1 to 5 wherein the compound is not *N*-(2-propenyl) – 5,8,11,14-eicosatetraenamide.
- 20 12. The use, compound or method of any of the previous claims wherein, in the compound of formula I, *n* represents 0 or 1.
13. The use, compound or method of claim 12 wherein, in the compound of formula I, *n* represents 1
- 25 14. The use, compound or method of any of claims 1 to 4 wherein the compound is *N*-(2-propenyl) hexadecanamide, *N*-(2-propenyl) cis-9-octadecenamide, *N*-(2-propenyl) cis-9-hexadecenamide, *N*-(2-propenyl) tetradecanamide, *N*-(2-propenyl) cis-9-tetradecenamide, *N*-(2-propenyl) octadecanamide, *N*-(2-propenyl) trans-9-
- 30

octadecenamide, *N*-(2-propenyl) dodecanamide, or *N*-(2-propenyl) cis-5-dodecenamide.

15. A use compound or method of any of the previous claims wherein  
5 the compound is *N*-(2-propenyl) hexadecanamide.

16. A pharmaceutical composition comprising a compound as defined in  
relation to any of the previous claims and one or more analgesics and  
a pharmaceutically acceptable excipient.

10

17. A kit of parts comprising:

(a) a compound as defined in relation to any of the previous claims;  
and,

15

(b) one or more analgesics; and,

(c) a pharmaceutically acceptable excipient

20

18. A use or method according to claim 4 or pharmaceutical composition  
according to claim 16 or a kit of parts according to claim 17 wherein  
the analgesic is an opioid, a non-steroidal anti-inflammatory drug, a  
local anaesthetic, a NMDA receptor antagonist, a cannabinoid, an  
antidepressant, and/or an anticonvulsant.

25